Neuraxis, Inc. (NRXS) - Total Assets
Based on the latest financial reports, Neuraxis, Inc. (NRXS) holds total assets worth $8.75 Million USD as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Neuraxis, Inc. - Total Assets Trend (2020–2025)
This chart illustrates how Neuraxis, Inc.'s total assets have evolved over time, based on quarterly financial data. Also see market value of Neuraxis, Inc. for the company's overall valuation and market capitalisation.
Neuraxis, Inc. - Asset Composition Analysis
Current Asset Composition (December 2025)
Neuraxis, Inc.'s total assets of $8.75 Million consist of 89.5% current assets and 10.5% non-current assets. Review Neuraxis, Inc. balance sheet liabilities to assess the company's total debt and financial obligations.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 77.5% |
| Accounts Receivable | $195.70K | 3.1% |
| Inventory | $257.13K | 4.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $274.78K | 4.3% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2020–2025)
This chart illustrates how Neuraxis, Inc.'s asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. See today's stock price for Neuraxis, Inc. for real-time trading data and today's change.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Neuraxis, Inc.'s current assets represent 89.5% of total assets in 2025, an increase from 88.3% in 2020.
- Cash Position: Cash and equivalents constituted 77.5% of total assets in 2025, up from 68.0% in 2020.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 4.0% of total assets, an increase from 0.0% in 2020.
- Asset Diversification: The largest asset category is intangible assets at 4.3% of total assets.
Neuraxis, Inc. Competitors by Total Assets
Key competitors of Neuraxis, Inc. based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
argenx NV ADR
NASDAQ:ARGX
|
USA | $10.03 Billion |
|
Madrigal Pharmaceuticals Inc
NASDAQ:MDGL
|
USA | $1.26 Billion |
|
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252
|
China | CN¥37.98 Billion |
|
Halozyme Therapeutics Inc
NASDAQ:HALO
|
USA | $2.22 Billion |
|
Tubize-Fin
BR:TUB
|
Belgium | €1.99 Billion |
|
Aurinia Pharmaceuticals Inc
NASDAQ:AUPH
|
USA | $792.26 Million |
|
Nanobiotix
NASDAQ:NBTX
|
USA | $67.76 Million |
|
Innovita Biological Technology Co. Ltd. A
SHG:688253
|
China | CN¥2.23 Billion |
Neuraxis, Inc. - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 2.89 | 1.21 | 0.34 |
| Quick Ratio | 2.81 | 1.19 | 0.32 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $5.33 Million | $439.82K | $-933.85K |
Neuraxis, Inc. - Advanced Valuation Insights
This section examines the relationship between Neuraxis, Inc.'s asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 27.78 |
| Latest Market Cap to Assets Ratio | 13.26 |
| Asset Growth Rate (YoY) | 34.6% |
| Total Assets | $6.40 Million |
| Market Capitalization | $84.91 Million USD |
Valuation Analysis
Premium Asset Valuation: The market values Neuraxis, Inc.'s assets at a significant premium (13.26x), suggesting investors see substantial growth potential or unique competitive advantages.
Rapid Asset Growth: Neuraxis, Inc.'s assets grew by 34.6% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Neuraxis, Inc. (2020–2025)
The table below shows the annual total assets of Neuraxis, Inc. from 2020 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $6.40 Million | +34.61% |
| 2024-12-31 | $4.76 Million | +833.78% |
| 2023-12-31 | $509.50K | -65.59% |
| 2022-12-31 | $1.48 Million | +94.70% |
| 2021-12-31 | $760.48K | -72.74% |
| 2020-12-31 | $2.79 Million | -- |
About Neuraxis, Inc.
NeurAxis, Inc., a medical technology company, focuses on developing neuromodulation therapies to address chronic and debilitating conditions in children and adults in the United States. It offers IB-Stim, a percutaneous electrical nerve field stimulation system intended to be used in patients 8 years of age with functional abdominal pain associated with irritable bowel syndrome (IBS), functional … Read more